Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1998-09-10
2001-10-23
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C800S008000, C800S021000
Reexamination Certificate
active
06306831
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the modulation of gene expression in embryos via the transplacental delivery of oligonucleotides. This invention also relates to methods of determining the function of a gene using non-human mammalian gene knockout models produced via transplacental delivery of oligonucleotides to non-human mammalian embryos.
BACKGROUND OF THE INVENTION
With the rapidly growing database of gene sequence information, there is a need for techniques that can rapidly and efficiently attribute function in vivo. To date, in a mammalian model, the only solution has been the generation of transgenic knockout animals. Knockout animal models such as mice and rats are a powerful tool in studying the role genes play during development. In these models, a targeted gene is made non-functional, resulting in an altered phenotype. This phenotype may be indicative of the function of the gene and the role it plays during development. However, the transgenic knockout method suffers from several significant drawbacks, including technical difficulty, time required, the limitation to single gene targets, and the inability to uncover time-dependent secondary phenotypes.
Currently, the most widely used approach in which such knockouts are created is disruption of the gene by genetic recombination with exogenous DNA (Mansour (1990)
Genet. Anal. Tech. App.
7:219-227; Robertson (1991)
Biol. Reprod.
44:238-245; Zimmer (1992)
Ann. Rev. Neurosci.
15:115-137). In this process oocytes collected from an animal stimulated to superovulate are transfected with the exogenous DNA. Recombination occurs, resulting in an oocyte with a non-functional gene. The oocyte is then fertilized, and implanted back into the animal. All subsequent progeny of these transformed animals will contain a disrupted target gene. However, this procedure suffers from several significant drawbacks. The transgenic knockout method is expensive, complex, and time consuming. In addition, the recombination event is limited to a point early in development. Finally, the technique is not capable of targeting more than one gene at a time, except as mating events between the eventual progeny of two separate recombination knockout animals.
Another method which has been used to create animal knockouts is the treatment of embryos in vitro with antisense RNA (Brice et al. (1993)
Dev. Genet
14:174-184) or DNA (Brice et al. (1993)
Dev. Genet.
14:174-184; Ochiya et al. (1995)
J CellBiol.
130:997-1003; Chen et al. (1995)
Biol. Reprod.
53:1229-1238; Augustine et al. (1995)
Teratol.
51:300-310; Stutz et al. (1997)
Mol. Cell. Biol.
17:1759-1767). Antisense approaches have the advantage of disrupting gene expression at the level of mRNA, resulting in the equivalent of a homozygous knockout phenotype. However, the methodology currently used is also expensive, complex, and time-consuming, in that it requires manipulation and growth of embryos in an artificial in vitro environment. It would be a distinct advantage to be able to administer oligonucleotides to pregnant mice in order to generate phenotypic knockouts directly, rather than treat embryos in vitro. The obvious barrier to this is the placenta.
Thus, improved methods of producing knockout models and of defining and studying gene function are still needed.
Antisense oligonucleotides have shown promise as candidates for therapeutic applications for diseases and disorders resulting from expression of cellular genes (see, e.g., WO 95/09236, WO 94/26887, and PCT/US/13685). Synthetic antisense oligonucleotides have also been demonstrated to be useful tools in inhibiting a wide variety of viruses (see, e.g., Agrawal (1992)
Trends Biotech.
10: 152-158). The development of various antisense oligonucleotides as therapeutic and diagnostic agents has recently been reviewed by Agrawal and Iyer (
Current Opinion Biotech.
(1995) 6:12-19). More recently, the antisense approach has been found to be useful for therapeutic treatment in vivo (see e.g., Agrawal (1996)
TIBTECH
14:376-387; Monia et al. (1996)
Nature Medicine
2:668-675; Crooke et al. (1996)
Ann. Rev. Pharmacol. Med.
36:107-129).
However, neither the treatment of embryos for viral infections or aberrant gene expression nor the modulation of embryonic genes or foreign genes harbored by embryos have heretofore been successfully accomplished in utero via the antisense approach. Such demonstrations become important when devising noninvasive therapeutic methods and informative in vivo models for human disease. It has been shown that phosphorothioate-modified oligonucleotides injected into pregnant female mice are not toxic or teratogenic to embryos in a non-specific way (Gaudette et al. (1993)
Antisense Res. Dev.
3:391-397).
Accordingly, there remains a need for effective gene-specific antisense oligonucleotide therapy suitable for treatment in mammalian embryos.
SUMMARY OF THE INVENTION
It has been discovered that modified synthetic oligonucleotides, when administered systemically to a pregnant mammal, can pass through its placenta to an embryo in utero, where modulation of the expression of a target gene is effectuated. The ramifications of this discovery are expected to change the strategy currently used for treating infections, diseases, and disorders caused by aberrant gene-specific expression in embryos. This discovery has been exploited to develop the present invention which includes methods of modulating gene expression and of delivering intact synthetic oligonucleotides to an embryo in utero, and concomitantly, to its mother; methods and knockout models for determining gene function; and methods for producing such models.
Synthetic oligonucleotides that are useful for transplacental delivery are oligonucleotides which are DNA or RNA or both, preferably between 12-35 nucleotides in length, having a stabilized and charged backbone and at least one chemically modified base or sugar moiety, wherein the modified base or sugar moiety facilitates transplacental delivery.
As an illustration, an oligonucleotide with phosphodiester internucleotide linkages is an oligonucleotide with a non-stabilized backbone. Such constructs are not stable and are degraded in vivo. Oligonucleotides with phosphorothioate modified internucleotide linkages are stable and persist in maternal tissue. In another illustration, oligonucleotides with methyl phosphonate internucleotide linkages exemplify a non-charged oligonucleotide variant that is inactive in this system. An illustration of a successfully modified base or sugar moiety would be a 2′-O-methyl ribonucleotide.
Additional illustrations will further elucidate the invention. Oligonucleotides modified with phosphorothioate alone are stable but do not cross the placenta (Gaudette et al. (1993)
Antisense Res. Dev.
3:391-397). Inverted chimeric oligonucleotides that are comprised of a phosphorothioate core region flanked by regions of phosphodiester at the 5′ and 3′ ends are not effective because their phosphodiester linkages are not sufficiently stabilized, and are degraded in vivo. A phosphorothioate backbone is charged, but needs a further modification to the base or bases to facilitate transplacental delivery. At least one 2′-O-methyl ribonucleotide is such a modification, although any 2′ substitution that successfully facilitates transplacental delivery is contemplated. A preferred embodiment is a phosphorothioate oligonucleotide containing at least one 2′-O-methyl modified ribonucleotide. This preferred composition is effective as it is both stabilized and modified for transplacental uptake.
REFERENCES:
patent: 4689320 (1987-08-01), Kaji
patent: 4806463 (1989-02-01), Goodchild
patent: 5149797 (1992-09-01), Pederson
patent: 5194428 (1993-03-01), Agrawal
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 6025193 (2000-02-01), Weiss
patent: WO 9706662 (1997-02-01), None
James, W. Towards Gene-Inhibition Therapy: A Review of Progress and Prospects in the Field of Antiviral Antisense Nucleic Acids and Ribozymes. Antiviral Chemistry & Ch
Driver Samuel E.
Roberts Peter C.
Hale and Dorr LLP
Priebe Scott D.
QIK Technologies, Inc.
LandOfFree
Transplacental delivery of oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transplacental delivery of oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transplacental delivery of oligonucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2580345